USE OF ERIBULIN AND CYCLIN DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER

• 收藏
• 分享

专利权人:

EISAI R&；D MANAGEMENT CO.; LTD.

发明人:

Bruce A. LITTLEFIELD,Gary HENDLER

申请号：

US16631207

公开号：

US20200129473A1

申请日:

2018.07.23

申请国别(地区):

US

年份:

2020

代理人:

摘要：

The invention features methods for treating and preventing cancer (e.g., an estrogen receptor-positive (ER+) breast cancer) in a patient in need thereof by administering eribulin (e.g., eribulin mesylate) in combination with a cyclin dependent kinase (CDK) inhibitor.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/